# A Study Called ARAMON to Learn to What Extent Does Study Treatment With Darolutamide Affects Testosterone Levels in Men With Prostate Cancer That Had Not Been Treated With Hormonal Therapy Compared to Treatment With Enzalutamide

> **NCT05526248** · PHASE2 · COMPLETED · sponsor: **Bayer** · enrollment: 28 (actual)

## Conditions studied

- Biochemically Recurrent Prostate Cancer

## Interventions

- **DRUG:** Darolutamide(BAY1841788, Nubeqa)
- **DRUG:** Enzalutamide

## Key facts

- **NCT ID:** NCT05526248
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-12-19
- **Primary completion:** 2024-08-20
- **Final completion:** 2024-12-04
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2026-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05526248

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05526248, "A Study Called ARAMON to Learn to What Extent Does Study Treatment With Darolutamide Affects Testosterone Levels in Men With Prostate Cancer That Had Not Been Treated With Hormonal Therapy Compared to Treatment With Enzalutamide". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05526248. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*